Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Narrative)

v3.10.0.1
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Number of shares acquired in exchange for common stock   31,745,242     2,090,301      
Precentage of issued and outstanding common stock diluted basis   90.00%            
Common stock issued     38,674,265   38,674,265   35,272,626  
Common stock shares outstanding     38,674,265   38,674,265   35,272,626  
Accumulated deficit     $ (7,014,961)   $ (7,014,961)   $ (3,859,086)  
Net income loss     852,822 $ 711,567 3,155,874 $ 1,222,453    
Net Cash Used In Operating Activities         3,243,938 978,823    
Cash and cash equivalents     2,424,223 $ 1,037,365 2,424,223 $ 1,037,365 $ 2,847,429 $ 1,071,894
Clinical Trial Funding commitment from investor capital     $ 1,800,000   1,800,000      
Additional Paid-In Capital [Member]                
Net income loss              
CoNCERT Pharmaceuticals, Inc [Member]                
Number of shares acquired in exchange for common stock 2,090,301              
Option exercised in exchange for common stock $ 8,000,000              
Percentage of royalty 15.00%              
Proceeds from royalty receivable $ 8,000,000              
Controlling interest, description Promet’s controlling interest was reduced from 90% to 84%.              
CoNCERT Pharmaceuticals, Inc [Member] | Option and License Agreement [Member]                
Option exercised in exchange for common stock $ 8,000,000              
CoNCERT Pharmaceuticals, Inc [Member] | Option and License Agreement [Member] | Additional Paid-In Capital [Member]                
Proceeds from royalty receivable $ 8,000,000